JPRN-jRCTs031220169招募中2 期
A multicenter, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with mpox or smallpox.
Morioka Shinichiro0 个研究点目标入组 50 人开始时间: 2022年6月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who can provide written consent for participation in the study.
- •2) Male or female patients whose weight is 13kg or more.
- •3)Patients who are diagnosed with mpox or smallpox.However, smallpox is diagnosed when the pathogen is detected in a blister, pustule, crust,pharyngeal swab, or blood specimen, etc., and Mpox is diagnosed when the pathogen is detected in a skin or mucosal lesion, blister contents, nasopharyngeal swab, pharyngeal swab, anorectal swab, other mucosal swab, blood, urine, or other materials suitable for the test method, by the following methods. The diagnosis is made when pathogens are detected in pharyngeal swab fluid, anorectal swab fluid, other mucous membrane swab fluid, blood, urine, or other materials suitable for the test metho
- •d by the following methods
- •-Direct observation of virus particles by electron microscopy
- •-Detection of pathogens by isolation and identification
- •-Detection of pathogen antigens by fluorescent antibody method
- •-Detection of pathogen genes by PCR method
- •4)Patients who agree to be hospitalised until the first Tecovirimat course of oral treatment is completed, if oral
- •Tecovirimat is administerd.
- •5) Patients with severe mpox or mpox with high risk of severe disease
- •All of 1)-3) must be met. As for mpox patients, 4) and 5) also must be met.
排除标准
- •1) Patients who have experienced any anaphylactic reaction to oral Tecovirimat or its ingredients.
- •2)Patients whom the study doctor considered to be ineligible.
- •Note 1) breast-feeding females will be counseled that tecovirimat has not been studied in breast-feeding women and may opt to cease breast-feedingfor the duration of the treatment and at least 30 days after the last dose of drug and thus be eligible for the treatment arm. Women who choose to continue breast-feeding will not be enrolled in the treatment arm.
- •Note 2) Although reproductive toxicity has not been adequately evaluated in animal studies, no cle
- •ar reproductive toxicity has been demonstrated to date. However, due to the lack of actual experience with administration to pregnant human women, the drug's package insert states that administration of Tecovilimat during pregnancy is not recommended. However, because there are no other candidates for effective treatment against mpox or smallpox, and because mpox can be transmitted transplacental to the fetus, causing miscarriage, premature delivery, or stillbirth, pregnant individuals should be fully aware of the above advantages and disadvantages of tecovirimat administration before they are eligible to participate as a dosing group The pregnant woman must fully understand the advantages and disadvantages of Tecovilimat administration described above to be eligible to participate in the study.
- •Note 3) In the case that a patient in the non-treatment arm wishes to join the treatment arm, the patient will be allowed to do so if the study doctor judges appropriate, after withdrawing the consent and providing another written consent.
研究者
相似试验
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-003172-41-CZovartis Pharma AG40
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyEUCTR2020-003172-41-FRovartis Pharma AG40
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients who are naïve to complement inhibitor therapy.Paroxysmal Nocturnal Hemoglobinuria (PNH).MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-003172-41-ITOVARTIS PHARMA AG40
进行中（未招募）
1 期
se of Fostemsavir in HIV-1 infected children and adolescents with Multi Drug-Resistant virusHIV-1 infection in children and adolescents with Multi Drug-Resistant virusMedDRA version: 20.1Level: LLTClassification code 10020447Term: Human immunodeficiency virus type I infection with other conditionsSystem Organ Class: 100000004862EUCTR2020-001029-30-ESFondazione Penta ONLUS60
招募中
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code: 10079841Term: Atypical hemolytic uremic syndrome Class: 10005329Atypical hemolytic uremic syndromeCTIS2023-508840-22-00ovartis Pharma AG44